NNVC - NanoViricides, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
1.03
+0.02 (+1.98%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.01
Open1.01
Bid0.97 x 1000
Ask0.00 x 0
Day's Range1.01 - 1.07
52 Week Range0.94 - 1.64
Volume163,745
Avg. Volume86,043
Market Cap65.21M
Beta-0.07
PE Ratio (TTM)-6.44
EPS (TTM)-0.16
Earnings DateNov 13, 2017 - Nov 17, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.30
Trade prices are not sourced from all markets
  • NanoViricides to Present Results On Successful Treatment Of Herpes-Induced Acute Retinal Necrosis at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology
    PR Newswire2 days ago

    NanoViricides to Present Results On Successful Treatment Of Herpes-Induced Acute Retinal Necrosis at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology

    SHELTON, Conn., Oct. 17, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company") will present the results of its anti-herpes nanoviricide treatment for Viral Acute Retinal Necrosis (vARN) at the 2017 Annual meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology to be held in New Orleans, LA. The abstract of the study has been accepted for presentation at this OMIG meeting on November 10th, 2017.  Dr. Vivien Boniuk, consultant in ophthalmology at NanoViricides, Inc. will make the scientific presentation.  The presentation will cover both the inhibition of virus infection and prevention of ocular tissue damage following virus infection.

  • NanoViricides Has Filed Annual Report, Says Company Has Sufficient Cash To Advance Into Clinical Trials
    PR Newswire20 days ago

    NanoViricides Has Filed Annual Report, Says Company Has Sufficient Cash To Advance Into Clinical Trials

    SHELTON, Conn., Sept. 29, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), reports that it has filed its financial year end annual report (Form 10-K) with the Securities and Exchange Commission (SEC) on Thursday, September 28, 2017 in a timely manner. NanoViricides, Inc. is a global leader in the application of nanomedicine technologies to the complex issues of viral diseases. The nanoviricide® technology enables direct attacks at multiple points on a virus particle.

  • NanoViricides, Inc. Announces its CEO Dr. Seymour to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City on September 12, 2017
    PR Newswirelast month

    NanoViricides, Inc. Announces its CEO Dr. Seymour to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City on September 12, 2017

    SHELTON, Conn., Sept. 11, 2017 /PRNewswire/ -- NanoViricides, Inc., (NYSE "NNVC") today announced it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  The conference is being held on September 10-12, 2017 at Lotte New York Palace Hotel in New York City. If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link (www.rodmanevents.com) to register for the Rodman & Renshaw conference.  Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

  • NanoViricides Reports Its Drug Candidates Significantly Reduced the Extent of Shingles Virus Infection of Human Skin
    PR Newswire3 months ago

    NanoViricides Reports Its Drug Candidates Significantly Reduced the Extent of Shingles Virus Infection of Human Skin

    SHELTON, Conn., July 10, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") reports that its anti-shingles nanoviricides® drug candidates achieved dramatic reduction in infection of human skin by the varicella-zoster virus (VZV), the shingles virus. The antiviral effect of certain nanoviricide drug candidates was substantially greater than the effect of the standard positive control of cidofovir added into media.

  • NanoViricides' Poster "Novel Nanoviricides® Highly Effective Against Varicella Zoster Virus in Cell Culture" to be Presented Today at the 2017 Annual Meeting of American Society of Virology
    PR Newswire4 months ago

    NanoViricides' Poster "Novel Nanoviricides® Highly Effective Against Varicella Zoster Virus in Cell Culture" to be Presented Today at the 2017 Annual Meeting of American Society of Virology

    SHELTON, Conn., June 26, 2017 /PRNewswire/ -- NanoViricides, Inc., (NYSE MKT: NNVC) (the "Company"), a pioneer in developing anti-viral nanomedicine drugs, is pleased to announce that its poster entitled "Novel Nanoviricides® Highly Effective Against Varicella Zoster Virus in Cell Culture" will be presented today at the 36th Annual Meeting of the American Society of Virology (ASV). Dr. Brian Friedrich, Senior Virologist of the Company, is presenting the Company's work on the evaluation of nanoviricides drug candidates for effectiveness against the shingles virus (Varicella Zoster Virus, VZV, aka Human HerpesVirus-3 or HHV-3) in this poster.

  • NanoViricides Abstract Accepted for Poster Presentation at the 2017 Annual Meeting of American Society of Virology
    PR Newswire4 months ago

    NanoViricides Abstract Accepted for Poster Presentation at the 2017 Annual Meeting of American Society of Virology

    SHELTON, Conn., June 20, 2017 /PRNewswire/ -- NanoViricides, Inc., (NYSE MKT: NNVC) (the "Company"), a pioneer in developing anti-viral nanomedicine drugs, is pleased to announce that its late-breaking abstract submission has been accepted for a poster presentation at the 36th Annual Meeting of the American Society of Virology (ASV). The ASV Meeting will be hosted and held at the University of Wisconsin-Madison, from June 24th to 28th, 2017 (https://extensionconferencecenters.uwex.edu/asv2017/). Dr. Brian Friedrich, Senior Virologist of the Company, will present the Company's work on the evaluation of nanoviricides drug candidates for effectiveness against the shingles virus (Varicella Zoster Virus, VZV, aka Human HerpesVirus-3 or HHV-3).

  • NanoViricides CEO to Present Information on Its Topical Shingles Treatment At the 2017 Marcum Investor Conference in New York City
    PR Newswire4 months ago

    NanoViricides CEO to Present Information on Its Topical Shingles Treatment At the 2017 Marcum Investor Conference in New York City

    SHELTON, Conn., June 13, 2017 /PRNewswire/ -- NanoViricides, Inc., (NYSE MKT: NNVC) (the "Company"), a pioneer in developing anti-viral nanomedicine drugs, reports that its CEO, Eugene Seymour, MD, MPH., will describe the Company's progress towards human clinical trials stage at the 2017 Marcum Investor Conference. The Company has recently reported that its drug candidates for topical treatment of shingles were almost five times more effective compared to acyclovir in cell culture studies.

  • NanoViricides Reports Excellent Inhibitory Effects of Its Topical Shingles Treatment Candidates Against VZV in Multiple Cell Culture Studies
    PR Newswire4 months ago

    NanoViricides Reports Excellent Inhibitory Effects of Its Topical Shingles Treatment Candidates Against VZV in Multiple Cell Culture Studies

    SHELTON, Conn., June 6, 2017 /PRNewswire/ -- NanoViricides, Inc., (NYSE MKT: NNVC) (the "Company"), a pioneer in developing anti-viral nanomedicine drugs, reports that its topical drug candidates in development for the treatment of shingles have demonstrated excellent inhibition of the causative virus with practically no cytotoxicity in cell culture assays using multiple cell lines. Two of the nanoviricide drug candidates in the HerpeCide™ program demonstrated almost complete inhibition of the varicella-zoster virus (VZV) at the highest drug doses, whereas acyclovir at the same drug dose exhibited partial inhibition of the virus.

  • Associated Press5 months ago

    NanoViricides reports 3Q loss

    On a per-share basis, the West Haven, Connecticut-based company said it had a loss of 5 cents. The company's shares closed at $1.24. A year ago, they were trading at $1.55. _____ This story was generated ...

  • NanoViricides Files Quarterly Report for Period Ending 2017-03-31
    PR Newswire5 months ago

    NanoViricides Files Quarterly Report for Period Ending 2017-03-31

    SHELTON, Conn., May 16, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), filed the quarterly report for its third quarter of financial year 2017 in a timely manner with the Securities and Exchange Commission on Monday, May 15th. NanoViricides reported that it had approximately $16.74 Million (M) of current assets (cash, cash equivalents, and prepaid expenses) as of March 31, 2017, the end of the reporting period. Briefly, holders of $5,000,000 principal value Series B Convertible Debentures, namely, an entity controlled by Dr. Milton Boniuk, a director of the Company, and The Boniuk Charitable Foundation, converted $5,000,000 of Series B debentures into equity, and the remaining $1,000,000 principal, with accrued interest as of the maturity date, was repaid to the holders thereof in cash, on or about.

  • NanoViricides CEO Dr. Seymour to Present an Update on the Company at The Planet Microcap Showcase - 2017 in Las Vegas; Company Says it is Close to Declaring a Clinical Candidate for the Treatment of Shingles
    PR Newswire6 months ago

    NanoViricides CEO Dr. Seymour to Present an Update on the Company at The Planet Microcap Showcase - 2017 in Las Vegas; Company Says it is Close to Declaring a Clinical Candidate for the Treatment of Shingles

    SHELTON, Conn., April 26, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), reports that Eugene Seymour, MD, MPH, CEO, will present information about the Company and its progress towards human trials at the Planet Microcap conference at the Planet Hollywood Hotel. NanoViricides, Inc. is a global leader developing antiviral nanomedicines for the treatment of a number of different viral infections. The Company is currently focused on developing its broad spectrum anti-herpesvirus drug candidates.

  • PR Newswire8 months ago

    NanoViricides Files Quarterly Report for Period Ending 2016-12-31

    SHELTON, Conn., Feb. 16, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), filed its quarterly report for its second quarter of financial year 2017 in a timely manner with the Securities and Exchange Commission on Tuesday, February 14th. NanoViricides reported that it had approximately $19.44 Million (M) of current assets (cash, cash equivalents, and prepaid expenses) as of December 31, 2016, the end of the reporting period. The net cash used in operating activities during this quarter was approximately $2.6 M. The Company's research and development (R&D) expenditure has increased as we advance towards human clinical trials.

  • Associated Press8 months ago

    NanoViricides reports 2Q loss

    On a per-share basis, the Shelton, Connecticut-based company said it had a loss of 3 cents. Losses, adjusted for non-recurring gains, were 4 cents per share. The company's shares closed at $1.17. A year ...

  • PR Newswire8 months ago

    NanoViricides Reports the Company's Director Dr. Boniuk Converted Series B Debenture to Equity Effectively Raising $5M in New Equity for the Company

    SHELTON, Conn., Feb. 13, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), reports today that a substantial portion of its Series B Convertible Debentures, with a maturity date of January 31, 2017, have been converted into restricted common stock, effectively retaining $5 million in cash for the Company. The Company offered a conversion proposal to all holders of the Series B Convertible Debentures, with a total principal value of $6,000,000. An entity controlled by Dr. Boniuk and the Boniuk Charitable Foundation accepted the Company's offer to convert debentures in the aggregate principal amount of $5,000,000.

  • PR Newswire11 months ago

    NanoViricides Publishes a Letter from the CEO to Shareholders on its Website

    SHELTON, Conn., Dec. 1, 2016 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), announced today that it has published a letter from the Company's CEO addressing its shareholders on its website (www.nanoviricides.com). In this letter, Dr. Eugene Seymour, CEO of the Company, surveys the Company's accomplishments in the past fiscal year that ended June 2016, and more recent events. The letter describes the progress that the Company has made towards entering human clinical trials.

  • PR Newswire11 months ago

    NanoViricides Files Quarterly Report for Period Ending 2016-09-30

    SHELTON, Conn., Nov. 15, 2016 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), filed its quarterly report for its first quarter of financial year 2017 in a timely manner with the Securities and Exchange Commission on Monday, November 14th. NanoViricides reported that it had approximately $22.1 Million (M) of current assets (cash, cash equivalents, and prepaid expenses) as of September 30, 2016, the end of the reporting period. The Company's research and development (R&D) expenditure has increased as we advance towards human clinical trials.

  • PR Newswire11 months ago

    NanoViricides President Dr. Diwan Gave Invited Talks on Regulatory Aspects of Nanomedicines

    SHELTON, Conn., Nov. 7, 2016 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), reports that its President Dr. Anil Diwan was recently invited to participate in certain pharmaceutical ...

  • PR Newswirelast year

    NanoViricides Signs Agreement with SUNY Upstate Medical Center for Testing of Its Drug Candidates for the Treatment of Shingles

    SHELTON, Conn., Oct. 31, 2016 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC (the "Company") announced today that it has entered into an agreement with SUNY Upstate Medical University for the testing of its nanoviricides® drug candidates against varicella zoster virus, i.e. The research will be performed in the laboratory of Dr. Jennifer Moffat and will include in vitro, ex vivo and possibly in vivo studies. Dr. Moffat has extensive experience in varicella zoster virus (VZV) infection and antiviral agent discovery. The goal of these studies is to help select a clinical drug development candidate for toxicology and safety evaluation intended for clinical trials for the treatment of shingles in humans.